Compared with gemcitabine, mFOLFIRINOX improved outcomes for all endpoints when used in the adjuvant setting.
Six months of maintenance chemotherapy improved OS in children with high-risk rhabdomyosarcoma.
The combination of the PARP inhibitor olaparib and abiraterone offered improved efficacy in patients with metastatic castration-resistant prostate cancer, but at what cost?
Nab-paclitaxel/carboplatin should be considered a first-line option in the setting of triple-negative breast cancer.
An avelumab combination therapy shows promise against ALK-driven lung cancers, but another was neither safe nor effective in non–ALK-driven cases.
The HER2 TKI tucatinib plus capecitabine or trastuzumab were reasonably well tolerated and showed antitumor activity in a phase I trial of HER2+ breast cancer.
Researchers in Hong Kong found dacomitinib was associated with longer OS than gefitinib in patients with advanced EGFR+ NSCLC.
Cell-free DNA, used to guide treatment of advanced lung cancer, may become a tool for early detection, based on analysis of participants in the Circulating Cell-free Genome Atlas study.
CAR T-cell therapy with bb2121 induced deep, long-lasting responses in patients with heavily pretreated MM.
OS with the PSA-targeted, poxvirus-based cancer vaccine was no better than placebo, and increased survival was attributed to better standard of care.